Concordia International Competitors

Concordia International (TSE:CXR) and Cronos Group (TSE:CRON) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Concordia International and Cronos Group, as provided by MarketBeat.

Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%.

Profitability

This table compares Concordia International and Cronos Group's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Concordia International and Cronos Group's top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Cronos Group on 4 of the 5 factors compared between the two stocks.

Concordia International (TSE:CXR) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Concordia International and Trillium Therapeutics, as provided by MarketBeat.

Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 91.42%.

Profitability

This table compares Concordia International and Trillium Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Concordia International and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Trillium Therapeutics on 4 of the 4 factors compared between the two stocks.

Concordia International (TSE:CXR) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Concordia International and Aptose Biosciences, as provided by MarketBeat.

Aptose Biosciences has a consensus price target of C$12.00, suggesting a potential upside of 81.54%.

Profitability

This table compares Concordia International and Aptose Biosciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Concordia International and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Aptose Biosciences on 3 of the 4 factors compared between the two stocks.

Concordia International (TSE:CXR) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Valuation and Earnings

This table compares Concordia International and Burcon NutraScience's top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Burcon NutraScience. Concordia International is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Concordia International and Burcon NutraScience's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Concordia International and Burcon NutraScience, as provided by MarketBeat.

Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 7.75%.

Summary

Concordia International beats Burcon NutraScience on 3 of the 5 factors compared between the two stocks.

Theratechnologies (TSE:TH) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Earnings & Valuation

This table compares Theratechnologies and Concordia International's top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and Concordia International's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Theratechnologies and Concordia International, as provided by MarketBeat.com.

Theratechnologies currently has a consensus price target of C$3.75, suggesting a potential downside of 21.38%.

Summary

Concordia International beats Theratechnologies on 4 of the 4 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Earnings & Valuation

This table compares BELLUS Health and Concordia International's top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Concordia International's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BELLUS Health and Concordia International, as provided by MarketBeat.com.

Summary

Concordia International beats BELLUS Health on 4 of the 5 factors compared between the two stocks.